TUL01101 

TUL01101 is a potent, selective and orally active JAK1 inhibitor, with an IC₅₀s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. TUL01101 can be used for the research of rheumatoid arthritis^[1].

TUL01101 (pretreatment for 1 h) inhibits cytokine-induced pSTAT in human whole blood assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TUL01101 (1-30 mg/kg; p.o. twice daily for 14 d) inhibits rheumatoid arthritis in the rat adjuvant-induced arthritis (AIA) model^[1].
TUL01101 (15 mg/kg; p.o. twice daily for 14 d) inhibits rheumatoid arthritis in collagen-induced arthritis models^[1].
TUL01101 (15 mg/kg; p.o.) exhibits T_1/2 of 2.01 h, C_max of 5105 nM, and oral bioavailability of 38.1% in mice^[1].
TUL01101 (10 mg/kg; p.o.) exhibits T_1/2 of 3.06 h, C_max of 4965 nM, and oral bioavailability of 121% in rats^[1].
TUL01101 (5 mg/kg; p.o.) exhibits T_1/2 of 4.49 h, C_max of 2750 nM, and oral bioavailability of 106.5% in dogs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

429.46

C₂₂H₂₅F₂N₅O₂

2411222-97-2

O=C(NC1=NN2C(C=CC=C2C3CCC4(CC3)CN(C4)C([C@@H]5CC5(F)F)=O)=N1)C6CC6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhou S, et, al. Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis. J Med Chem. 2022 Dec 22;65(24):16716-16740.  [Content Brief]